Format

Send to

Choose Destination
Sci Rep. 2017 Jan 5;7:40187. doi: 10.1038/srep40187.

Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma.

Author information

1
Department of Oral and Maxillofacial Pathobiology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
2
Department of Oral Molecular Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
3
Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan.
4
Department of Orthopaedic Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
5
Division of Orthopaedic Surgery, National Hospital Organization Kure Medical Center, Kure, Japan.
6
Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
7
Center of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima, Japan.

Abstract

Ameloblastin (AMBN), the most abundant non-amelogenin enamel matrix protein, plays a role in ameloblast differentiation. Previously, we found that AMBN promoted osteogenic differentiation via the interaction between CD63 and integrin β1, leading to the inactivation of Src; however, how AMBN affects the malignant behavior of osteosarcoma is still unclear. Osteosarcoma affects the bone and is associated with poor prognosis because of the high rate of pulmonary metastases and drug resistance. Here we demonstrated that stable overexpression of AMBN induced apoptosis and suppressed colony formation and cell migration via the inactivation of Src-Stat3 pathway in human osteosarcoma cells. Moreover, AMBN induced chemosensitivity to doxorubicin. Thus, AMBN induced a tumor suppressive phenotype and chemosensitivity to doxorubicin via the AMBN-Src-Stat3 axis in osteosarcoma. Indeed, immunohistochemical expression of AMBN was significantly correlated with better outcome of osteosarcoma patients. Our findings suggest that AMBN can be a new prognostic marker and therapeutic target for osteosarcoma combined with conventional doxorubicin treatment.

PMID:
28054649
PMCID:
PMC5214574
DOI:
10.1038/srep40187
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center